TABLE 1.

Primary lesion resolution in and survival of mice that received VIGa

Vaccinia virus dose (PFU)No. of VIG-treated miceNo. (%) with primary lesion healingNo. (%) of survivors at 120 days
1066636 (55)0
1051410 (71)6 (43)
1041815 (83)13 (72)
  • a Mice received VIG (10 mg/mouse on days 2, 5, 10, and 15 after vaccinia virus infection) and were challenged with 106, 105, or 104 PFU of vaccinia virus. Using a two-tailed chi-square test, the primary lesion healing endpoint was significantly different between the 106 and 104 PFU challenge groups (P = 0.0266) but not between the 106 and 105 PFU (P = 0.2458) or the 105 and 104 PFU (P = 0.4190) groups. Likewise, survival differed significantly (P < 0.001) between the 106 PFU challenge group and either the 105 PFU or the 104 PFU challenge group but not between the 105 and 104 PFU groups (P = 0.0934).